Dihydroergotoxine Methanesulfonate
Dihydroergotoxine Methanesulfonate Brand names, Dihydroergotoxine Methanesulfonate Analogs
- Alkergot
- Circanol
- Co-Dergocrine Mesylate
- Deapril-ST
- Dihydroergotoxin Mesilat
- Dihydroergotoxin Mesylate
- Dihydroergotoxin Methanesulfonate
- Dihydroergotoxine Mesilate
- Dihydroergotoxine Mesylate
- Dihydroergotoxine Methanesulfonate
- Dihydroergotoxine Methanesulphonate
- Ergoloid Mesylates [Usan]
- Gerimal
- Hydergin
- Hydergine
- Hydergine LC
- Hydrogenated Ergot Alkaloids
- Ischelium
- Redergin
- Trigot
Dihydroergotoxine Methanesulfonate Brand Names Mixture
- No information avaliable
Dihydroergotoxine Methanesulfonate Chemical_Formula
C33H45N5O5
Dihydroergotoxine Methanesulfonate RX_link
No information avaliable
Dihydroergotoxine Methanesulfonate fda sheet
Dihydroergotoxine Methanesulfonate msds (material safety sheet)
Dihydroergotoxine Methanesulfonate Synthesis Reference
No information avaliable
Dihydroergotoxine Methanesulfonate Molecular Weight
591.741 g/mol
Dihydroergotoxine Methanesulfonate Melting Point
No information avaliable
Dihydroergotoxine Methanesulfonate H2O Solubility
No information avaliable
Dihydroergotoxine Methanesulfonate State
Solid
Dihydroergotoxine Methanesulfonate LogP
2.615
Dihydroergotoxine Methanesulfonate Dosage Forms
Capsule; Liquid; Powder; Powder for solution; Solution; Syrup; Tablet
Dihydroergotoxine Methanesulfonate Indication
For use as an adjunct therapy for patients with dementia
Dihydroergotoxine Methanesulfonate Pharmacology
Ergoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia.
Dihydroergotoxine Methanesulfonate Absorption
Rapidly but incompletely (approximately 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism.
Dihydroergotoxine Methanesulfonate side effects and Toxicity
Symptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia.
Dihydroergotoxine Methanesulfonate Patient Information
No information avaliable
Dihydroergotoxine Methanesulfonate Organisms Affected
Humans and other mammals
